- Home
- DBD vs NRIX Comparison
DBD vs NRIX Comparison
Compare DBD & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DBD | NRIX |
|---|---|---|
| Founded | 1859 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.5B |
| IPO Year | 2023 | 2020 |
Fundamental Metrics
Financial Performance| Metric | DBD | NRIX |
|---|---|---|
| Price | $69.94 | $26.72 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 12 |
| Target Price | ★ $90.00 | $30.50 |
| AVG Volume (30 Days) | 299.4K | ★ 999.6K |
| Earning Date | 04-30-2026 | 04-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 677.27 | N/A |
| EPS | ★ 0.58 | N/A |
| Revenue | ★ $3,805,700,000.00 | $76,987,000.00 |
| Revenue This Year | $3.56 | N/A |
| Revenue Next Year | $3.25 | $48.05 |
| P/E Ratio | $116.91 | ★ N/A |
| Revenue Growth | 1.46 | ★ 99.31 |
| 52 Week Low | $54.48 | $8.20 |
| 52 Week High | $92.09 | $28.23 |
Technical Indicators
Market Signals| Indicator | DBD | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 37.60 | 64.21 |
| Support Level | $67.63 | $14.63 |
| Resistance Level | $72.41 | N/A |
| Average True Range (ATR) | 2.53 | 0.98 |
| MACD | -0.44 | 0.02 |
| Stochastic Oscillator | 24.71 | 75.95 |
Price Performance
Historical ComparisonAbout DBD Diebold Nixdorf Incorporated
Diebold Nixdorf Inc is engaged in providing software and hardware services for financial and retail industries. The customer segments of the company are Banking, which offers integrated solutions for financial institutions, and Retail, which offers solutions, software, and services that improve the checkout process for retailers. A majority of its revenue is generated from the Banking segment.
About NRIX Nurix Therapeutics Inc.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.